Figure 2
From: Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Distribution of 264 eyes (229 patients) with neovascular age-related macular degeneration treated at a university medical centre in 2012–2014 for which an application was made to the national health insurance system for funding of treatment with ranibizumab. (a) Distribution by age. *P < 0.05 versus 50–59 years. (b) Distribution by year and month at application. *P < 0.05 versus January to June 2012. (c) Distribution by clinician according to years of experience in ophthalmological practice. *P < 0.05; senior clinicians #1 and #2 versus junior clinicians #3, #4, and #5.
